Hypoxia-sensitive drug delivery to tumors

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Effective cancer chemotherapy requires high drug concentration in tumors with minimal systemic toxicity.
• Tumor hypoxia is a key characteristic that can be exploited for targeted drug delivery.
• Stimuli-responsive drug delivery systems aim to improve therapeutic outcomes by releasing drugs specifically at the tumor site.

Purpose of the Study:

• To develop and evaluate a hypoxia-sensitive micellar nanoparticle system (PEG-azobenzene-PEI-DOPE, PAPD) for targeted cancer drug delivery.
• To investigate the ability of PAPD to selectively release its payload under hypoxic conditions, enhancing cellular uptake and therapeutic efficacy.
• To assess the in vivo performance of PAPD in reducing tumor growth and systemic side effects.

Main Methods:

• Fabrication of PEG-azobenzene-PEI-DOPE (PAPD) nanoparticles.
• In vitro evaluation of PAPD's stimuli-responsive behavior and cellular uptake using microfluidics in 2D and 3D tumor models under hypoxic conditions.
• In vivo studies using an animal model to assess tumor growth inhibition and systemic toxicity compared to free drug treatment.

Main Results:

• PAPD nanoparticles demonstrated hypoxia-induced PEG layer shedding, leading to enhanced cellular association and penetration in both 2D and 3D tumor models.
• In vivo administration of PAPD resulted in significant tumor growth inhibition without observable systemic side effects, such as weight loss.
• The system successfully co-delivered doxorubicin and siRNA targeting P-glycoprotein, showcasing its potential for combination therapy.

Conclusions:

• The developed PAPD system is an effective hypoxia-targeted drug delivery platform for cancer therapy.
• PAPD offers a promising strategy for improving chemotherapy by enhancing tumor drug accumulation and minimizing systemic toxicity.
• This versatile platform can be adapted for delivering various chemotherapeutic agents and siRNA molecules for enhanced cancer treatment.